| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Korean J Urol Oncol > Volume 11(3); 2013 > Article
The Korean Journal of Urological Oncology 2013;11(3): 128-132.
호르몬민감성 전립선암 환자의 치료에 있어서 간헐적 남성호르몬박탈요법이 지속적 남성호르몬박탈요법에 비해 좋은 치료법인가?
김선일, 김세중
아주대학교 의과대학 비뇨기과학교실
Is Intermittent Androgen Deprivation Therapy a Better Treatment Than Continuous Androgen Deprivation Therapy in the Treatment of Patients with Hormone-Sensitive Prostate Cancer?
Sun Il Kim , Se Joong Kim
Department of Urology, Ajou University School of Medicine, Suwon, Korea
Published online: December 30, 2013.
ABSTRACT
Accumulated experience indicates that intermittent androgen deprivation (IADT) is an acceptable treatment option for patients with prostate cancer that need ADT. Compared to continuous ADT (CADT), IADT has the advantages of being more economic and less detrimental to the quality of life, and shows similar efficacy in terms of overall survival and disease progression. For this reason, European Association of Urology Guideline and National Comprehensive Cancer Network Guideline recommend its use for the treatment of prostate cancer. Recently, several randomized phase 3 trials comparing IADT with CADT have been published (SEUG9401, TAP22, FinnProstate VII, NCT3653, SEUG9901 and SWOG9346). These heterogeneous studies have shown that IADT is at least non-inferior to CADT in terms of overall survival and disease progression, except for the SWOG9346 trial which was unable to rule out that IADT may decrease overall survival by 20% compared to CADT. The effect of IADT on quality of life was positive with many studies demonstrating significantly better quality of life score compared to CADT. However, these studies should be criticized for not being able to show any prolongation of time to progression as has been shown in the experimental settings. New studies with different designs should elicit undiscovered effectiveness of IADT in the future. For the time being, IADT should be considered in every patient who could potentially benefit from recovery of testosterone, but the method of IADT should be individualized rather than strictly abide by the arbitrarily set criteria in the randomized trial settings. (Korean J Urol Oncol 2013;11:128-132)
Key Words: Prostate cancer; Androgens; Antineoplastic hormonal drugs; Survival; Quality of life
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society.                 Developed in M2PI
Close layer
prev next